Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
12.76
+1.30 (11.34%)
At close: Jun 6, 2025, 4:00 PM
12.60
-0.16 (-1.25%)
After-hours: Jun 6, 2025, 7:04 PM EDT
Lyell Immunopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Cash & Equivalents | 120.33 | 105.6 | 145.65 | 123.55 | 293.83 | 140.41 | Upgrade
|
Short-Term Investments | 180.85 | 264.93 | 400.58 | 516.6 | 320.97 | 472.21 | Upgrade
|
Cash & Short-Term Investments | 301.18 | 370.53 | 546.22 | 640.15 | 614.79 | 612.62 | Upgrade
|
Cash Growth | -42.77% | -32.17% | -14.67% | 4.13% | 0.36% | 40.49% | Upgrade
|
Prepaid Expenses | 8 | 9.07 | 8.46 | 11.14 | 11.49 | 4.93 | Upgrade
|
Total Current Assets | 309.18 | 379.59 | 554.69 | 651.3 | 626.29 | 617.55 | Upgrade
|
Property, Plant & Equipment | 67.77 | 72.94 | 142.32 | 166.27 | 166.64 | 124.06 | Upgrade
|
Long-Term Investments | 47.95 | 32.01 | 48.51 | 115.04 | 330.53 | 163.44 | Upgrade
|
Other Long-Term Assets | 4.91 | 6.31 | 4.52 | 4.96 | 3.95 | 3.24 | Upgrade
|
Total Assets | 429.8 | 490.86 | 750.03 | 937.56 | 1,127 | 908.28 | Upgrade
|
Accounts Payable | 3.73 | 5.37 | 4.82 | 3.92 | 3.21 | 9.4 | Upgrade
|
Accrued Expenses | 22.93 | 29.37 | 20.36 | 21.14 | 22.36 | 17.84 | Upgrade
|
Current Portion of Leases | 8.24 | 7.97 | 6.27 | 4.53 | 1.17 | 3.62 | Upgrade
|
Current Unearned Revenue | - | - | - | - | 4.99 | 6.1 | Upgrade
|
Other Current Liabilities | 6.39 | 11.08 | 3.07 | 7.44 | 15.01 | 12.34 | Upgrade
|
Total Current Liabilities | 41.29 | 53.79 | 34.52 | 37.03 | 46.74 | 49.29 | Upgrade
|
Long-Term Leases | 48.85 | 50.99 | 56.89 | 63.17 | 66.65 | 50.96 | Upgrade
|
Long-Term Unearned Revenue | - | - | - | - | 79.67 | 89.07 | Upgrade
|
Other Long-Term Liabilities | 3.14 | 3.25 | 3.66 | 4.11 | 4.57 | 0.53 | Upgrade
|
Total Liabilities | 93.28 | 108.04 | 95.08 | 104.31 | 197.62 | 189.84 | Upgrade
|
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0 | Upgrade
|
Additional Paid-In Capital | 1,734 | 1,728 | 1,657 | 1,608 | 1,516 | 41.36 | Upgrade
|
Retained Earnings | -1,397 | -1,345 | -1,002 | -767.48 | -584.36 | -334.14 | Upgrade
|
Comprehensive Income & Other | 0.16 | 0.29 | -0.09 | -7.6 | -1.62 | 0.26 | Upgrade
|
Total Common Equity | 336.52 | 382.82 | 654.95 | 833.25 | 929.79 | -292.53 | Upgrade
|
Shareholders' Equity | 336.52 | 382.82 | 654.95 | 833.25 | 929.79 | 718.44 | Upgrade
|
Total Liabilities & Equity | 429.8 | 490.86 | 750.03 | 937.56 | 1,127 | 908.28 | Upgrade
|
Total Debt | 57.09 | 58.97 | 63.17 | 67.7 | 67.82 | 54.57 | Upgrade
|
Net Cash (Debt) | 273.04 | 324.57 | 499.56 | 642.57 | 830.51 | 638.04 | Upgrade
|
Net Cash Growth | -41.22% | -35.03% | -22.25% | -22.63% | 30.16% | 43.84% | Upgrade
|
Net Cash Per Share | 20.10 | 24.83 | 39.81 | 52.01 | 122.21 | 962.50 | Upgrade
|
Filing Date Shares Outstanding | 14.77 | 14.76 | 12.7 | 12.48 | 12.14 | 0.89 | Upgrade
|
Total Common Shares Outstanding | 14.76 | 14.74 | 12.7 | 12.48 | 12.14 | 0.78 | Upgrade
|
Working Capital | 267.89 | 325.81 | 520.17 | 614.27 | 579.55 | 568.26 | Upgrade
|
Book Value Per Share | 22.79 | 25.97 | 51.58 | 66.78 | 76.61 | -375.76 | Upgrade
|
Tangible Book Value | 336.52 | 382.82 | 654.95 | 833.25 | 929.79 | -292.53 | Upgrade
|
Tangible Book Value Per Share | 22.79 | 25.97 | 51.58 | 66.78 | 76.61 | -375.76 | Upgrade
|
Machinery | - | 39.03 | 35.85 | 34.33 | 29.03 | 17.99 | Upgrade
|
Construction In Progress | - | 0.24 | 0.13 | 4.15 | 10.58 | 55.71 | Upgrade
|
Leasehold Improvements | - | 79.61 | 118.32 | 116.93 | 95 | 8.45 | Upgrade
|
Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.